{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:24:28Z","timestamp":1794353068027,"version":"4.9.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"989","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>For those facing progressive life limiting disease, symptoms across a range of systems can be problematic. Clinicians may find themselves prescribing from several classes of drugs to alleviate distressing problems and to maximise quality of life for patients. Many drugs used for symptom control in palliative care give rise to neuropsychiatric side effects as they affect the central nervous system either directly or indirectly. The common unwanted effects of these drugs are well known, but there are some important neuropsychiatric effects that physicians are less aware of. If unrecognised, these effects can generate considerable distress and unnecessary harm to patients. We aim to highlight some of the adverse neuropsychiatric effects which occur with commonly used drugs in palliative care. Antiemetics such as metoclopramide and haloperidol can cause significant levels of neuropsychiatric toxicity, as can opiates, antidepressants, anxiolytics and antipsychotics. The syndromes or entities that will be considered are delirium, drug induced parkinsonism, akathisia, serotonin syndrome and neuroleptic malignant syndrome. The intention is to alert clinicians to the iatrogenic complications which may ensue on prescribing drugs commonly used in the palliative care setting.<\/jats:p>","DOI":"10.1136\/pgmj.2007.062117","type":"journal-article","created":{"date-parts":[[2008,3,27]],"date-time":"2008-03-27T17:28:04Z","timestamp":1206638884000},"page":"121-126","source":"Crossref","is-referenced-by-count":40,"title":["Neuropsychiatric complications of commonly used palliative care drugs"],"prefix":"10.1093","volume":"84","author":[{"given":"N","family":"Jackson","sequence":"first","affiliation":[{"name":"Northern Ireland Hospice Care , Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Doherty","sequence":"additional","affiliation":[{"name":"Northern Ireland Hospice Care , Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Coulter","sequence":"additional","affiliation":[{"name":"Northern Ireland Hospice Care , Belfast, Northern Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,3,27]]},"reference":[{"key":"2023041909420907700_bib1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/pgmj.2006.052431","article-title":"Delirium","volume":"83","author":"Harris","year":"2007","journal-title":"Postgrad Med J"},{"key":"2023041909420907700_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1191\/0269216304pm879oa","article-title":"Delirium in advanced cancer patients","volume":"18","author":"Centeno","year":"2004","journal-title":"Palliat Med"},{"key":"2023041909420907700_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1089\/jpm.2006.9.422","article-title":"Symptom control in palliative care\u2014part III: dyspnea and delirium","volume":"9","author":"Del Fabbro","year":"2006","journal-title":"J Palliat Med"},{"key":"2023041909420907700_bib4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archinte.160.6.786","article-title":"Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study","volume":"160","author":"Lawlor","year":"2000","journal-title":"Arch Intern Med"},{"key":"2023041909420907700_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00002512-199915010-00002","article-title":"Drug-induced cognitive impairment in the elderly","volume":"15","author":"Moore","year":"1999","journal-title":"Drugs Aging"},{"key":"2023041909420907700_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/pgmj.2003.017236","article-title":"An approach to drug induced delirium in the elderly","volume":"80","author":"Alagiakrishnan","year":"2004","journal-title":"Postgrad Med J"},{"key":"2023041909420907700_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/jpm.2006.0112","article-title":"First do no harm, terminal restlessness and delirium","volume":"10","author":"White","year":"2007","journal-title":"J Palliat Med"},{"key":"2023041909420907700_bib8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000017180","article-title":"Drugs that induce delirium","volume":"10","author":"Karlsson","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2023041909420907700_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000017166","article-title":"Neurochemistry and delirium","volume":"10","author":"Koponen","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"2023041909420907700_bib10","volume-title":"Delirium, acute confusional state","author":"Lipowski","year":"1990"},{"key":"2023041909420907700_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1517\/14740338.5.6.759","article-title":"Drug-induced parkinsonism","volume":"5","author":"Mena","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"2023041909420907700_bib12","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199908000-00007","article-title":"Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics","volume":"19","author":"Caligiuri","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"2023041909420907700_bib13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00002512-200017050-00004","article-title":"Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations","volume":"17","author":"Caligiuri","year":"2000","journal-title":"Drugs Aging"},{"key":"2023041909420907700_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1474-4422(05)70226-X","article-title":"Prevalence of movement disorders in men and women aged 50\u201389 years (Bruneck study cohort): a population-based study","volume":"4","author":"Wenning","year":"2005","journal-title":"Lancet Neurol"},{"key":"2023041909420907700_bib15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/mds.20806","article-title":"Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study)","volume":"21","author":"Barbosa","year":"2006","journal-title":"Mov Disord"},{"key":"2023041909420907700_bib16","doi-asserted-by":"crossref","first-page":"iii22","DOI":"10.1007\/s00415-006-3004-8","article-title":"Drug induced parkinsonism: a review","volume":"253","author":"Hirose","year":"2006","journal-title":"J Neurol"},{"key":"2023041909420907700_bib17","first-page":"112","article-title":"[Drug-induced parkinsonism]","volume":"55","author":"Kuzuhara","year":"1997","journal-title":"Nippon Rinsho"},{"key":"2023041909420907700_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1191\/0269216306pm1118cr","article-title":"Prolonged extra-pyramidal side effects after discontinuation of haloperidol as an antiemetic","volume":"20","author":"White","year":"2006","journal-title":"Palliat Med"},{"key":"2023041909420907700_bib19","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/014107688507800910","article-title":"Drug-induced akathisia: a review","volume":"78","author":"Ball","year":"1985","journal-title":"J R Soc Med"},{"key":"2023041909420907700_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/1099-1166(200102)16:2<231::AID-GPS303>3.0.CO;2-Y","article-title":"Drug induced akathisia, suicidal ideation and its treatment in the elderly","volume":"16","author":"Hansen","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"2023041909420907700_bib21","first-page":"267","article-title":"[Three cases of drug-induced akathisia due to antiemetics during cancer palliative care]","volume":"33","author":"Tsuji","year":"2006","journal-title":"Gan To Kagaku Ryoho"},{"key":"2023041909420907700_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/003693300104600502","article-title":"Akathisia\u2014a brief review","volume":"46","author":"Nelson","year":"2001","journal-title":"Scott Med J"},{"key":"2023041909420907700_bib23","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/bmj.324.7352.1506","article-title":"Lesson of the week: Akathisia: overlooked at a cost","volume":"324","author":"Akagi","year":"2002","journal-title":"BMJ"},{"key":"2023041909420907700_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.psc.2004.10.004","article-title":"Neuroleptic-induced movement disorders: an overview","volume":"28","author":"Sachdev","year":"2005","journal-title":"Psychiatr Clin North Am"},{"key":"2023041909420907700_bib25","first-page":"5","article-title":"Acute akathisia in palliative care","volume":"12","author":"White","year":"2005","journal-title":"Eur J Palliat Care"},{"key":"2023041909420907700_bib26","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"4","key":"2023041909420907700_bib27","first-page":"CD003727","article-title":"Anticholinergics for neuroleptic-induced acute akathisia","volume":"2006","author":"Rathbone","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909420907700_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0924-977X(96)00041-7","article-title":"Risk factors for the development of neuroleptic induced akathisia","volume":"7","author":"Miller","year":"1997","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023041909420907700_bib29","volume-title":"Palliative care formulary","author":"Twycross","year":"2003","edition":"2nd ed"},{"key":"2023041909420907700_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1017\/S003329170003960X","article-title":"The pathophysiology of extrapyramidal side-effects of neuroleptic drugs","volume":"10","author":"Marsden","year":"1980","journal-title":"Psychol Med"},{"key":"2023041909420907700_bib31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5694\/j.1326-5377.2002.tb04387.x","article-title":"Mirtazapine-induced akathisia","volume":"176","author":"Girishchandra","year":"2002","journal-title":"Med J Aust"},{"key":"2023041909420907700_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0006-3223(94)91257-2","article-title":"A rating scale for acute drug-induced akathisia: development, reliability, and validity","volume":"35","author":"Sachdev","year":"1994","journal-title":"Biol Psychiatry"},{"key":"2023041909420907700_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00004850-200015040-00004","article-title":"Clinical correlates of akathisia in acute psychiatric inpatients","volume":"15","author":"Berardi","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"2023041909420907700_bib34","author":"Kendell","year":"1994","edition":"5th ed"},{"key":"2023041909420907700_bib35","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hup.325","article-title":"A critical review of akathisia, and its possible association with suicidal behaviour","volume":"16","author":"Hansen","year":"2001","journal-title":"Hum Psychopharmacol"},{"key":"2023041909420907700_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2850.2006.00908.x","article-title":"Pharmacological management of akathisia in combination with psychological interventions by a mental health nurse consultant","volume":"13","author":"Jones","year":"2006","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"2023041909420907700_bib37","volume-title":"Kaplan and Sadock's synopsis of psychiatry","author":"Sadock","year":"2003","edition":"9th ed"},{"key":"2023041909420907700_bib38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/schbul\/21.3.431","article-title":"The epidemiology of drug-induced akathisia: part I. Acute akathisia","volume":"21","author":"Sachdev","year":"1995","journal-title":"Schizophr Bull"},{"key":"2023041909420907700_bib39","volume-title":"Palliative care formulary","author":"Twycross","year":"2003","edition":"2nd ed"},{"key":"2023041909420907700_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1046\/j.1526-4637.2003.03005.x","article-title":"Serotonin syndrome and other serotonergic disorders","volume":"4","author":"Ener","year":"2003","journal-title":"Pain Med"},{"key":"2023041909420907700_bib41","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.biopsych.2005.11.016","article-title":"A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action","volume":"59","author":"Gillman","year":"2006","journal-title":"Biol Psychiatry"},{"key":"2023041909420907700_bib42","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ajem.2005.02.018","article-title":"Identifying serotonin syndrome in the emergency department","volume":"23","author":"Christensen","year":"2005","journal-title":"Am J Emerg Med"},{"key":"2023041909420907700_bib43","first-page":"871","article-title":"Antidepressants and the serotonin syndrome in general practice","volume":"49","author":"Mackay","year":"1999","journal-title":"Br J Gen Pract"},{"key":"2023041909420907700_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-199819030-00002","article-title":"Adverse effects of opioid agonists and agonist-antagonists in anaesthesia","volume":"19","author":"Bowdle","year":"1998","journal-title":"Drug Saf"},{"key":"2023041909420907700_bib45","first-page":"97","article-title":"Serotonin syndrome: a hidden danger in palliative care","volume":"12","author":"Anderson","year":"2005","journal-title":"Eur J Palliat Care"},{"key":"2023041909420907700_bib46","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0736-4679(98)00057-2","article-title":"Treatment of the serotonin syndrome with cyproheptadine","volume":"16","author":"Graudins","year":"1998","journal-title":"J Emerg Med"},{"key":"2023041909420907700_bib47","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N Engl J Med"},{"key":"2023041909420907700_bib48","first-page":"309","article-title":"The serotonin syndrome","volume":"62","author":"Bijl","year":"2004","journal-title":"Neth J Med"},{"key":"2023041909420907700_bib49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/bja\/aei210","article-title":"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity","volume":"95","author":"Gillman","year":"2005","journal-title":"Br J Anaesth"},{"key":"2023041909420907700_bib50","first-page":"1439","article-title":"Serotonin syndrome: a brief review","volume":"168","author":"Birmes","year":"2003","journal-title":"CMAJ"},{"key":"2023041909420907700_bib51","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am J Psychiatry"},{"key":"2023041909420907700_bib52","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1054\/mehy.2000.1047","article-title":"An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria","volume":"55","author":"Radomski","year":"2000","journal-title":"Med Hypotheses"},{"key":"2023041909420907700_bib53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00005792-200007000-00001","article-title":"Serotonin syndrome. Presentation of 2 cases and review of the literature","volume":"79","author":"Mason","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"2023041909420907700_bib54","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0749-0704(05)70368-7","article-title":"Serotonin syndrome. A clinical update","volume":"13","author":"Mills","year":"1997","journal-title":"Crit Care Clin"},{"key":"2023041909420907700_bib55","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"Q J Med"},{"key":"2023041909420907700_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/(SICI)1520-6394(1997)5:2<84::AID-DA4>3.0.CO;2-5","article-title":"Clomipramine augmentation in treatment-resistant depression","volume":"5","author":"Amsterdam","year":"1997","journal-title":"Depress Anxiety"},{"key":"2023041909420907700_bib57","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1176\/appi.psy.42.3.258","article-title":"Possible serotonin syndrome in association with 5-HT(3) antagonist agents","volume":"42","author":"Turkel","year":"2001","journal-title":"Psychosomatics"},{"key":"2023041909420907700_bib58","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1345\/aph.1A161","article-title":"Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction","volume":"36","author":"Fisher","year":"2002","journal-title":"Ann Pharmacother"},{"key":"2023041909420907700_bib59","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1345\/aph.1C228","article-title":"Combination risperidone and SSRI-induced serotonin syndrome","volume":"37","author":"Karki","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"1\u20132","key":"2023041909420907700_bib60","first-page":"97","article-title":"Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome \u2013 a case report","volume":"18","author":"Supe","year":"2006","journal-title":"Psychiatr Danub"},{"key":"2023041909420907700_bib61","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1345\/aph.1H301","article-title":"Neuroleptic malignant syndrome with delayed onset of fever following risperidone administration","volume":"40","author":"Norris","year":"2006","journal-title":"Ann Pharmacother"},{"key":"2023041909420907700_bib62","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1592\/phco.26.8.1180","article-title":"Olanzapine-associated neuroleptic malignant syndrome","volume":"26","author":"Norgard","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2023041909420907700_bib63","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0031-3955(16)35003-9","article-title":"Phenothiazine and butyrophenone intoxication in children","volume":"33","author":"Knight","year":"1986","journal-title":"Pediatr Clin North Am"},{"key":"2023041909420907700_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1017\/S147895150505008X","article-title":"Neuroleptic malignant syndrome in cancer treatment","volume":"3","author":"Kawanishi","year":"2005","journal-title":"Palliat Support Care"},{"key":"2023041909420907700_bib65","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1089\/jpm.2004.7.861","article-title":"Neuroleptic malignant syndrome after haloperidol and fentanyl infusion in a patient with cancer with severe mineral imbalance","volume":"7","author":"Morita","year":"2004","journal-title":"J Palliat Med"},{"key":"2023041909420907700_bib66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2007-979328","article-title":"Delirium and persistent dyskinesia induced by a lithium-neuroleptic interaction","volume":"31","author":"Normann","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"2023041909420907700_bib67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/01.BCR.0000202644.17987.3F","article-title":"Neuroleptic malignant syndrome associated with metoclopramide in a burn patient","volume":"27","author":"Nachreiner","year":"2006","journal-title":"J Burn Care Res"},{"key":"2023041909420907700_bib68","first-page":"1359","article-title":"[Malignant neuroleptic syndrome under metoclopramide and neuroleptics in anuria]","volume":"123","author":"Krahenbuhl","year":"1993","journal-title":"Schweiz Med Wochenschr"},{"key":"2023041909420907700_bib69","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0090-8258(92)90037-J","article-title":"Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy","volume":"44","author":"Bakri","year":"1992","journal-title":"Gynecol Oncol"},{"key":"2023041909420907700_bib70","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1445-5994.1995.tb01542.x","article-title":"Delayed neuroleptic malignant syndrome following cessation of prolonged therapy with metoclopramide","volume":"25","author":"Le Couteur","year":"1995","journal-title":"Aust N Z J Med"},{"key":"2023041909420907700_bib71","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-199609000-00009","article-title":"Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents","volume":"11","author":"Spivak","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"2023041909420907700_bib72","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1176\/appi.ajp.163.3.547-b","article-title":"Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal","volume":"163","author":"Tanii","year":"2006","journal-title":"Am J Psychiatry"},{"key":"2023041909420907700_bib73","first-page":"575","article-title":"[A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine]","volume":"46","author":"Hamada","year":"2006","journal-title":"Rinsho Shinkeigaku"},{"key":"2023041909420907700_bib74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08860220500461252","article-title":"Successful treatment of six patients with neuroleptic malignant syndrome associated with myoglobulinemic acute renal failure","volume":"28","author":"Sanai","year":"2006","journal-title":"Ren Fail"},{"key":"2023041909420907700_bib75","first-page":"435","article-title":"A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole","volume":"99","author":"Rodriguez","year":"2006","journal-title":"J Okla State Med Assoc"},{"key":"2023041909420907700_bib76","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0929-6646(09)60115-7","article-title":"Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder","volume":"105","author":"Lu","year":"2006","journal-title":"J Formos Med Assoc"},{"key":"2023041909420907700_bib77","first-page":"2155","article-title":"Neuroleptic malignant syndrome: a review and report of six cases","volume":"89","author":"Kasantikul","year":"2006","journal-title":"J Med Assoc Thai"},{"key":"2023041909420907700_bib78","first-page":"49","article-title":"Neuroleptic malignant syndrome due to olanzapine","volume":"35","author":"Hall","year":"2001","journal-title":"Psychopharmacol Bull"},{"key":"2023041909420907700_bib79","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archinte.1984.00350150243048","article-title":"Neuroleptic malignant syndrome and dopaminergic blockade","volume":"144","author":"Hashimoto","year":"1984","journal-title":"Arch Intern Med"},{"key":"2023041909420907700_bib80","first-page":"302","article-title":"Detection and management of the neuroleptic malignant syndrome","volume":"3","author":"Bond","year":"1984","journal-title":"Clin Pharm"},{"key":"2023041909420907700_bib81","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00007611-198603000-00018","article-title":"Neuroleptic malignant syndrome","volume":"79","author":"Rampertaap","year":"1986","journal-title":"South Med J"},{"key":"2023041909420907700_bib82","author":"Gurrera","year":"2003","journal-title":"Strategies for patients who are suspected of having acute neuroleptic malignant syndrome (NMS)"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/84\/989\/121\/50021347\/postgradmedj-84-121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/84\/989\/121\/50021347\/postgradmedj-84-121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:48:47Z","timestamp":1681897727000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/84\/989\/121\/7023482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,1]]},"references-count":82,"journal-issue":{"issue":"989","published-online":{"date-parts":[[2008,3,27]]},"published-print":{"date-parts":[[2008,3,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2007.062117","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,3]]},"published":{"date-parts":[[2008,3,1]]}}}